"FDA grants ODD to Tempest’s hepatocellular carcinoma treatment" was originally created and published by Pharmaceutical ...

The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

BGB-10188 is under clinical development by BeiGene and currently in Phase II for Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Renal Cell Carcinoma have a 29% phase transition ...

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, ...

Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications • NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Marginal Zone B-cell Lymphoma.

Future directions for the treatment of patients with nonresectable hepatocellular carcinoma from the Bologna Liver Oncology Group (BLOG). Exploring alternative intra-arterial treatments (such as ...

This manuscript offers valuable insights by identifying two distinct liver cancer subtypes through multi-omics integration and developing a robust prognostic model, validated across various datasets, ...